drugset / Trial / NCT06232096
A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I/Ⅱ, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics(PD) and efficacy of a novel asymmetric trivalent tri-specific humanized antibody, MBS314, administered by intravenous (IV) infusion in participants with relapsed or refractory multiple myeloma. This entry-to-human study is divided in 2 parts: a dose escalation part (Phase Ⅰa) and an expansion part (Phase Ⅰb/Ⅱ).
Timeline
- Start
- 2024-02-22
- Primary completion
- 2026-02
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MBS314 | Unknown | 0.03 mg | Intravenous |
| Subject | MBS314 | Unknown | 0.09 mg | Intravenous |
| Subject | MBS314 | Unknown | 0.3 mg | Intravenous |
| Subject | MBS314 | Unknown | 0.9 mg | Intravenous |
| Subject | MBS314 | Unknown | 1.5 mg | Intravenous |
| Subject | MBS314 | Unknown | 9 mg | Intravenous |
| Subject | MBS314 | Unknown | 60 mg | Intravenous |